Alexion Pharmaceuticals Inc. (ALXN) Initiates Multinational Registration Trial Of Eculizumab For The Prevention Of Delayed Graft Function (DGF) After Kidney Transplantation
8/25/2014 10:23:30 AM
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the initiation of dosing in a single, multinational, placebo-controlled clinical trial to evaluate the efficacy and safety of eculizumab (Soliris®) for the prevention of delayed graft function (DGF) after kidney transplantation in adult patients who are at increased risk of DGF. DGF is an early and serious complication of organ transplantation that affects approximately 25 percent,1 and possibly up to 50 percent,2 of deceased-donor kidney transplant cases, and is characterized by the failure of a transplanted organ to function normally immediately following transplantation. Patients experiencing DGF after a kidney transplant require dialysis in order to survive.3-5
Help employers find you! Check out all the jobs and post your resume.
comments powered by